Talk:Pharmaceutical Care Management Association

PCMA has been involved in the debate in the United States Congress regarding the approval of a pathway for generic biosimilar drugs or follow-on biologics. The Obama Administration has agreed with PCMA's position on biosimilars.[1] Mistersimpleton (talk) 14:51, 9 July 2009 (UTC)